A. Conley

发表

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

Mindy I. Davis, D. Baker, D. Hazuda, 2021, The Journal of infectious diseases.

Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.

J. Robinson, S. Zolla-Pazner, M. Gorny, 1997, AIDS research and human retroviruses.

Complement-Mediated Enhancement of Antibody Function for Neutralization of Pseudotype Virus Containing Hepatitis C Virus E2 Chimeric Glycoprotein

K. Meyer, R. Ray, A. Basu, 2002, Journal of Virology.

Antimicrobial Action of Esters of Polyhydric Alcohols

A. Conley, J. Kabara, 1973, Antimicrobial Agents and Chemotherapy.

Fatty Acids and Derivatives as Antimicrobial Agents

A. Conley, J. Truant, J. Kabara, 1972, Antimicrobial Agents and Chemotherapy.

Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters.

A. Davis, M. Lubeck, P. Hung, 1987, Proceedings of the National Academy of Sciences of the United States of America.

A transforming plasmid from HSV-2 transformed cells contains rat DNA homologous to the HSV-1 and HSV-2 genomes.

B. Bejcek, A. Conley, 1986, Virology.

Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys.

N. Letvin, E. Emini, T. Fuerst, 1993, Journal of immunology.

Cyclic V3-loop-related HIV-1 conjugate vaccines. Synthesis, conformation and immunological properties.

D. Underwood, M. Bednarek, E. Emini, 2009, International journal of peptide and protein research.

Distinctive properties of the hepatitis B virus envelope proteins

A. Davis, P. Hung, K. Molnar-Kimber, 1988, Journal of virology.

Distinctive Properties oftheHepatitis B VirusEnvelope Proteins

A. Davis, P. Hung, A. Conley, 1988 .

Herpes simplex virus cloned DNA fragments induce coumermycin A1 resistance in Escherichia coli

R. Pearson, A. Conley, 1984, Journal of virology.

Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression

H. Clifford Lane, Steven A. Rosenberg, H. Lane, 1995, Nature Medicine.

A physical domain of herpes simplex virus ICP8 is expressed and active in Escherichia coli

R. Pearson, B. Bejcek, A. Conley, 1985, Journal of virology.

Molecular genetics of herpes simplex virus. V. Characterization of a mutant defective in ability to form plaques at low temperatures and in a viral fraction which prevents accumulation of coreless capsids at nuclear pores late in infection

B. Roizman, D. Furlong, M. Tognon, 1981, Journal of virology.

Relationship of Chemical Structure and Antimicrobial Activity of Alkyl Amides and Amines

A. Conley, J. Truant, J. Kabara, 1972, Antimicrobial Agents and Chemotherapy.

Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens.

S. Bondy, A. Conley, S. Marburg, 1994, Vaccine.

Cloning of reiterated and nonreiterated herpes simplex virus 1 sequences as BamHI fragments.

B. Roizman, L. Post, E. Mocarski, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

W. Schleif, E. Emini, J. Nunberg, 1992, Nature.

cyt gene of adenoviruses 2 and 5 is an oncogene for transforming function in early region E1B and encodes the E1B 19,000-molecular-weight polypeptide

W. Wold, C. Cladaras, A. Conley, 1984, Journal of virology.

Molecular genetics of herpes simplex virus. VII. Characterization of a temperature-sensitive mutant produced by in vitro mutagenesis and defective in DNA synthesis and accumulation of gamma polypeptides

B. Roizman, D. Knipe, A. Conley, 1981, Journal of virology.

Use of Monoclonal Antibodies Against Two 75,000-Molecular-Weight Glycoproteins Specified by Herpes Simplex Virus Type 2 in Glycoprotein Identification and Gene Mapping

P. Spear, M. Weinberger, M. Para, 1983, Journal of virology.

Casting a wider net: Immunosurveillance by nonclassical MHC molecules

Timothy A. Gondré-Lewis, E. Adams, Y. Chien, 2019, PLoS pathogens.

A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B

A. Trkola, B. Korber, J. Moore, 1995, Journal of virology.

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

S. Zolla-Pazner, M. Gorny, E. Emini, 1994, Journal of virology.

Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody

S. Zolla-Pazner, M. Gorny, E. Emini, 1992, Journal of virology.

Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

E. Emini, P. Keller, J. Tung, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates.

E A Emini, D R Burton, C. Barbas, 1997, AIDS research and human retroviruses.

Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays.

J. Moore, D. Ho, J. Robinson, 1994, Journal of acquired immune deficiency syndromes.

Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1.

G. Scott, A. Conley, R. Geffin, 1998, AIDS research and human retroviruses.

In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160.

V. Tolstikov, S. Pincus, B. Wahrén, 1996, AIDS research and human retroviruses.

Identification and characterization of the herpes simplex virus type 2 gene encoding the essential capsid protein ICP32/VP19c

W. Wold, A. Conley, S. Yei, 1990, Journal of virology.

Enhancing the avidity of a human recombinant anti-HIV-1 monoclonal antibody through oligomerization.

M. Bruner, P. Tsai, J. Tung, 1995, Journal of pharmaceutical sciences.

Vaccine Protection against a Heterologous, Non-Syncytium-Inducing, Primary Human Immunodeficiency Virus

S. Zolla-Pazner, M. Robert-Guroff, F. Sinangil, 1998, Journal of Virology.

The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate

H. Katinger, W. Schleif, E. Emini, 1996, Journal of virology.

Induction of mutations in bacteria by a fragment of DNA from herpes simplex virus type 1.

E. Shillitoe, A. Conley, T. S. Matney, 1986, Virus research.

Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1

J. Sodroski, J. Moore, S. Zolla-Pazner, 1994, Journal of virology.

Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

S. Zolla-Pazner, M. Gorny, N. Michael, 1997, Journal of immunology.

Antimicrobial action of isomeric fatty acids on group A Streptococcus.

A. Conley, J. Kabara, D. Swieczkowski, 1973, Journal of medicinal chemistry.

ANTIMICROBIAL ACTION OF ISOMERIC FATTY ACIDS ON GROUP A STREPTOCOCCUS

F. Gunstone, I. A. Ismail, A. Conley, 1973 .

A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge

N. Letvin, E. Emini, R. Woods, 1995, Journal of virology.